Work

A Phase I Study of Escalated Dose Subcutaneous Alemtuzumab Given Weekly with Rituximab In Relapsed CLL/SLL.

Year: 2010

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v116.21.1381.1381

Authors: Jennifer R Brown, Bradley Messmer, Lillian Werner, Evgeny Mikler, David C. Fisher, Ann LaCasce, Philippe Armand, Eric D Jacobsen, Virginia Dalton, Bethany Tesar, Stacey M Fernandes, Sean McDonough, Jerome Ritz, Laura Z Rassenti, Thomas J. Kipps, Donna Neuberg, Arnold S. Freedman

Institutions: Harvard University, Dana-Farber Cancer Institute, University of California San Diego, Moores Cancer Center

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2594465420

FWCI: 0.26

Cites:

Cited by: 2

Related to: 10